Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT.
Arnon NaglerMyriam LabopinMutlu AratPéter ReményiYener KocDidier BlaiseEmanuele AngelucciJan VydraAleksandr KulaginGerard SociéMontserrat RoviraSimona SicaMahmoud AljurfZafer GülbasNicolaus KrögerEolia BrissotZinaida PericSebastian GiebelFabio CiceriMohamad MohtyPublished in: Cancer (2022)
Outcomes of MMUD and haplo transplants with PTCy-based GVHD prophylaxis for ALL patients in CR are similar, apart from a higher incidence of aGVHD with haplo transplants.
Keyphrases
- acute lymphoblastic leukemia
- stem cell transplantation
- end stage renal disease
- newly diagnosed
- bone marrow
- ejection fraction
- endothelial cells
- chronic kidney disease
- allogeneic hematopoietic stem cell transplantation
- high dose
- peripheral blood
- risk factors
- prognostic factors
- peritoneal dialysis
- cord blood
- acute myeloid leukemia
- systemic lupus erythematosus
- induced pluripotent stem cells
- insulin resistance
- weight loss